Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years.

British Journal of Haematology
Stéphane DucassouCentre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE)

Abstract

Childhood chronic immune thrombocytopenic purpura (cITP) is a rare disease. In severe cases, there is no evidence for the optimal therapeutic strategy. Our aim was to describe the real-life management of non-selected children with cITP at diagnosis. Since 2004, patients less than 18 years old with cITP have been enrolled in the national prospective cohort, OBS'CEREVANCE. From 1990 to 2014, in 29 centres, 392 children were diagnosed with cITP. With a median follow-up of six years (2·0-25), 45% did not need second-line therapy, and 55% (n = 217) received one or more second lines, mainly splenectomy (n = 108), hydroxychloroquine (n = 61), rituximab (n = 61) or azathioprine (n = 40). The overall five-year further second-line treatment-free survival was 56% [95% CI 49·5-64.1]. The use of splenectomy significantly decreased over time. Hydroxychloroquine was administered to children with positive antinuclear antibodies, more frequently older and girls, and reached 55% efficacy. None of the patients died. Ten years after the initial diagnosis, 55% of the 56 followed children had achieved complete remission. Children with cITP do not need second-line treatments in 45% of cases. Basing the treatment decision on the pathophysiological pat...Continue Reading

References

Nov 1, 2002·The Journal of Pediatrics·George R Buchanan, Leah Adix
Aug 26, 2006·Pediatric Blood & Cancer·Jelena Roganovic, Marina Letica-Crepulja
Aug 16, 2008·Hematology·A Paling, D C Stefan
Oct 30, 2009·Pediatric Hematology and Oncology·Fatih DemircioğluGülersu Irken
Nov 13, 2009·Pediatric Blood & Cancer·Deepak BansalR K Marwaha
Jan 6, 2010·International Journal of Hematology·Masaru KubotaTatsutoshi Nakahata
Feb 5, 2010·American Journal of Hematology·Deirdra R TerrellJames N George
Dec 25, 2010·The Journal of Clinical Investigation·Aude Magerus-ChatinetFrédéric Rieux-Laucat
Jan 14, 2011·Haematologica·Nathalie AladjidiUNKNOWN Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE)
Feb 18, 2011·Blood·Cindy NeunertUNKNOWN American Society of Hematology
Mar 27, 2012·La Revue de médecine interne·M MichelL Lévy-Bachelot
Jun 1, 2012·Pediatrics International : Official Journal of the Japan Pediatric Society·Eftichia StiakakiMaria Kalmanti
Oct 25, 2013·British Journal of Haematology·Marlène PasquetUNKNOWN Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE)
Jan 28, 2014·Journal of Autoimmunity·Cong YuChristopher Chang
Oct 21, 2015·Frontiers in Pediatrics·Nathalie AladjidiGuy Leverger
Mar 29, 2016·British Journal of Haematology·Matthew G BrowningMark Coleman
Feb 24, 2017·American Journal of Hematology·Ombeline RocheIsabelle Pellier
Apr 22, 2017·Autoimmunity Reviews·Sylvain AudiaBernard Bonnotte
Dec 12, 2017·Journal of Clinical Immunology·Aziz BousfihaKathleen E Sullivan
Jan 4, 2018·Blood·Shruti ChaturvediKeith R McCrae
Jan 14, 2018·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Caroline BesnardUNKNOWN Members of the French reference center for pediatric autoimmune cytopenias (CEREVANCE)
Apr 17, 2018·American Journal of Hematology·Rachael F GraceMichele P Lambert
Sep 18, 2018·Memo·Jan-Paul Bohn, Michael Steurer
Apr 4, 2019·Blood·Jérôme HadjadjUNKNOWN members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.